Live feed07:00:00·46dPRReleasevia QuantisnowKymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology CongressesByQuantisnow·Wall Street's wire, on your screen.KYMR· Kymera Therapeutics Inc.Health Care
